Companies › SNDX

SYNDAX PHARMACEUTICALS INC (SNDX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001395937 · EDGAR filings · Updated 2026-07-14

SYNDAX PHARMACEUTICALS INC (SNDX) has reported institutional ownership of 112.1%, with 245 institutional managers holding positions valued at $2.32B per the latest 13F reporting period.

Latest updates

• 2026-07-14 — Current report (8-K) filed
• 2026-07-09 — Insider transaction reported (Form 4)
• 2026-07-08 — Notice of proposed sale filed (Form 144)
• 2026-06-12 — Insider transaction reported (Form 4)
• 2026-06-12 — Notice of proposed sale filed (Form 144)
• 2026-06-11 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, SYNDAX PHARMACEUTICALS INC has 245 institutional holders and institutional ownership of 112.1%.

Insider activity

Insiders reported 33 transactions (4 buys, 10 sells) across 9 reporting insiders, with a net reported value of −$3.92M.

Related companies

LEMAITRE VASCULAR INC (LMAT) · BIOCRYST PHARMACEUTICALS INC (BCRX) · LIFESTANCE HEALTH GROUP INC (LFST) · LIQUIDIA CORPORATION COM NEW (LQDA) · STOKE THERAPEUTICS INC (STOK) · CELLDEX THERAPEUTICS INC NEW (CLDX)